Pliant Therapeutics downgraded to Hold from Buy at Canaccord

Canaccord analyst Edward Nash downgraded Pliant Therapeutics (PLRX) to Hold from Buy with a price target of $4, down from $43, after the company paused enrollment and dosing in the ongoing Phase 2b BEACON-IPF clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis following recommendations by the data safety monitoring board.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue